Focus: SecondWave Systems is a Minneapolis-based biotechnology company founded in 2020 specializing in noninvasive ultrasound treatment for infectious diseases and immunology indications. The company is early-stage with a focused pipeline targeting unmet needs in rheumatoid arthritis, COVID-19, and long COVID through splenic ultrasound stimulation.
Profile data last refreshed 13h ago · AI intelligence enriched 1mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
SecondWave represents a high-risk, high-reward opportunity best suited for founders-minded scientists willing to bet on novel ultrasound immunology in a bootstrapped or under-capitalized setting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for SecondWave Systems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from SecondWave Systems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo